- Home
- DYOR vs SLGL Comparison
DYOR vs SLGL Comparison
Compare DYOR & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DYOR | SLGL |
|---|---|---|
| Founded | 2025 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.8M | 218.9M |
| IPO Year | 2025 | 2016 |
Fundamental Metrics
Financial Performance| Metric | DYOR | SLGL |
|---|---|---|
| Price | $10.16 | $71.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $152.50 |
| AVG Volume (30 Days) | ★ 57.5K | 35.8K |
| Earning Date | 01-01-0001 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.87 | $28.81 |
| 52 Week High | $10.47 | $97.97 |
Technical Indicators
Market Signals| Indicator | DYOR | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 76.63 | 51.74 |
| Support Level | $9.93 | $69.09 |
| Resistance Level | $10.19 | $81.18 |
| Average True Range (ATR) | 0.01 | 4.60 |
| MACD | 0.00 | 0.93 |
| Stochastic Oscillator | 50.00 | 62.58 |
Price Performance
Historical ComparisonAbout DYOR Insight Digital Partners II Class A Ordinary Shares
Insight Digital Partners II is a blank check company.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.